Towards interpretable speech biomarkers: exploring MFCCs

While speech biomarkers of disease have attracted increased interest in recent years, a challenge is that features derived from signal processing or machine learning approaches may lack clinical interpretability. This study examined a commonly used feature, Mel Frequency Cepstral Coefficient 2 (MFCC), in two progressive brain diseases, Frontotemporal dementia and Parkinson’s disease. Data show sensitivity to disease of this feature can be increased by adjusting computation parameters.

This study was conducted in collaboration with Takeda, University of Melbourne, MIT, Monash and University of Rochester Medical Center.

To find out more about the study, click here.

Related Post

  • Posted on 29 September, 2025
    MEDIA RELEASE MELBOURNE, VIC – We’re pleased to share that Redenlab has been awarded $2.5 million in non-dilutive funding through...
    • Posted on 25 July, 2025
      A new clinical trial has found early evidence that a metabolic therapy could improve outcomes for people with ataxia-telangiectasia (A-T),...
      • Posted on 26 June, 2025
        Pain is deeply personal, yet universally expressed through speech. But what if speech isn’t just a way we describe pain,...